In two phase III randomized placebo-controlled BELLE-2 and BELLE-3 trials, the combination of buparlisib with fulvestrant was evaluated in HR-positive, HER2-negative postmenopausal breast cancer patients who progressed on AI or mTOR inhibitors. The gene discussed is ERBB2; the disease is breast carcinoma.